GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » ROE %

Enveric Biosciences (Enveric Biosciences) ROE % : -625.87% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Enveric Biosciences's annualized net income for the quarter that ended in Dec. 2023 was $-13.74 Mil. Enveric Biosciences's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $2.20 Mil. Therefore, Enveric Biosciences's annualized ROE % for the quarter that ended in Dec. 2023 was -625.87%.

The historical rank and industry rank for Enveric Biosciences's ROE % or its related term are showing as below:

ENVB' s ROE % Range Over the Past 10 Years
Min: -638.43   Med: -100.08   Max: -46.66
Current: -252.02

During the past 13 years, Enveric Biosciences's highest ROE % was -46.66%. The lowest was -638.43%. And the median was -100.08%.

ENVB's ROE % is ranked worse than
91.03% of 1360 companies
in the Biotechnology industry
Industry Median: -44.015 vs ENVB: -252.02

Enveric Biosciences ROE % Historical Data

The historical data trend for Enveric Biosciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences ROE % Chart

Enveric Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -52.42 -97.81 -380.82 -100.08 -208.22

Enveric Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -185.35 -149.61 -333.12 -308.79 -625.87

Competitive Comparison of Enveric Biosciences's ROE %

For the Biotechnology subindustry, Enveric Biosciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's ROE % distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's ROE % falls into.



Enveric Biosciences ROE % Calculation

Enveric Biosciences's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-17.311/( (14.672+1.956)/ 2 )
=-17.311/8.314
=-208.22 %

Enveric Biosciences's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-13.744/( (2.436+1.956)/ 2 )
=-13.744/2.196
=-625.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Enveric Biosciences  (NAS:ENVB) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-13.744/2.196
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-13.744 / 0)*(0 / 5.4595)*(5.4595 / 2.196)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*2.4861
=ROA %*Equity Multiplier
=N/A %*2.4861
=-625.87 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-13.744/2.196
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-13.744 / -13.656) * (-13.656 / -16.932) * (-16.932 / 0) * (0 / 5.4595) * (5.4595 / 2.196)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0064 * 0.8065 * N/A % * 0 * 2.4861
=-625.87 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Enveric Biosciences ROE % Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences (Enveric Biosciences) Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Executives
Frank Pasqualone director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney officer: Chief Financial Officer 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey officer: Chief Financial Officer 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil director C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson director 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel officer: Chief Technical Officer 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker director, officer: Chief Executive Officer 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini officer: Chief Scientific Officer 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward officer: Chief Financial Officer 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind director
Marcus Schabacker director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer director 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson director, officer: CEO and Chairman C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins officer: Chief Medical Officer C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103

Enveric Biosciences (Enveric Biosciences) Headlines

From GuruFocus